Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 12660

1.

Breast Cancer Prevention.

Euhus DM, Diaz J.

Breast J. 2014 Nov 20. doi: 10.1111/tbj.12352. [Epub ahead of print]

PMID:
25413630
[PubMed - as supplied by publisher]
2.

Incidence of metachronous contralateral breast cancer in Denmark 1978-2009.

Rasmussen CB, Kjær SK, Ejlertsen B, Andersson M, Jensen MB, Christensen J, Langballe R, Mellemkjær L.

Int J Epidemiol. 2014 Oct 16. pii: dyu202. [Epub ahead of print]

PMID:
25326461
[PubMed - as supplied by publisher]
3.

Risk of contralateral breast cancer after tamoxifen use among Danish women.

Mellemkjær L, Steding-Jessen M, Frederiksen K, Andersson M, Ejlertsen B, Jensen MB, Olsen JH.

Ann Epidemiol. 2014 Sep 6. pii: S1047-2797(14)00399-8. doi: 10.1016/j.annepidem.2014.08.003. [Epub ahead of print]

PMID:
25277504
[PubMed - as supplied by publisher]
4.

Exemestane with ovarian suppression in premenopausal breast cancer.

Prasad V.

N Engl J Med. 2014 Oct 2;371(14):1358. doi: 10.1056/NEJMc1409366#SA3. No abstract available.

PMID:
25271613
[PubMed - indexed for MEDLINE]
5.

Exemestane with ovarian suppression in premenopausal breast cancer.

Chlebowski RT, Pan K.

N Engl J Med. 2014 Oct 2;371(14):1358. doi: 10.1056/NEJMc1409366#SA2. No abstract available.

PMID:
25271612
[PubMed - indexed for MEDLINE]
6.

Exemestane with ovarian suppression in premenopausal breast cancer.

Amoroso V, Berruti A, Simoncini E.

N Engl J Med. 2014 Oct 2;371(14):1357. doi: 10.1056/NEJMc1409366#SA1. No abstract available.

PMID:
25271611
[PubMed - indexed for MEDLINE]
7.

Exemestane with ovarian suppression in premenopausal breast cancer.

Pagani O, Regan MM, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group.

N Engl J Med. 2014 Oct 2;371(14):1358-9. doi: 10.1056/NEJMc1409366. No abstract available.

PMID:
25271610
[PubMed - indexed for MEDLINE]
Free Article
8.

Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.

Maximov PY, McDaniel RE, Fernandes DJ, Bhatta P, Korostyshevskiy VR, Curpan RF, Jordan VC.

J Natl Cancer Inst. 2014 Sep 24;106(10). pii: dju283. doi: 10.1093/jnci/dju283. Print 2014 Oct.

PMID:
25258390
[PubMed - indexed for MEDLINE]
9.

More treatment options for women with hormone receptor-positive breast cancer: guideline update, studies lead to advances in care.

Printz C.

Cancer. 2014 Oct 1;120(19):2939-40. doi: 10.1002/cncr.29034. No abstract available.

PMID:
25241884
[PubMed - indexed for MEDLINE]
10.

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea.

Zhou J, Wu SG, Wang JJ, Sun JY, Li FY, Lin Q, Lin HX, He ZY.

Cancer Res Treat. 2014 Aug 21. doi: 10.4143/crt.2013.165. [Epub ahead of print]

PMID:
25187267
[PubMed - as supplied by publisher]
Free Article
11.

Analysis of radiation-induced angiosarcoma of the breast.

Zemanova M, Rauova K, Boljesikova E, Machalekova K, Krajcovicova I, Lehotska V, Mikulova M, Svec J.

Bratisl Lek Listy. 2014;115(5):307-10.

PMID:
25174061
[PubMed - indexed for MEDLINE]
12.

Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.

Ishizuna K, Ninomiya J, Ogawa T, Tsuji E, Kojima M, Kawashima M, Nozaki M, Yamagishi H, Ueda Y, Oya M.

Gan To Kagaku Ryoho. 2014 Aug;41(8):965-70.

PMID:
25132027
[PubMed - indexed for MEDLINE]
13.

A new combination therapy for premenopausal breast cancer.

Yaqub F.

Lancet Oncol. 2014 Jul;15(8):e311. No abstract available.

PMID:
25121178
[PubMed - indexed for MEDLINE]
14.

Lowering your breast cancer risk. A daily pill can hold the key to prevention for some women.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2014 Feb;25(15):1-2. No abstract available.

PMID:
25118364
[PubMed - indexed for MEDLINE]
15.

Toremifene in the treatment of breast cancer.

Mustonen MV, Pyrhönen S, Kellokumpu-Lehtinen PL.

World J Clin Oncol. 2014 Aug 10;5(3):393-405. doi: 10.5306/wjco.v5.i3.393. Review.

PMID:
25114854
[PubMed]
Free PMC Article
16.

[Breast cancer: radiotherapy and estrogen signaling].

Bourgier C, Lemanski C, Romieu G, Ozsahin M, Azria D.

Bull Cancer. 2014 Jul-Aug;101(7-8):714-7. doi: 10.1684/bdc.2014.1954. Review. French.

PMID:
25091654
[PubMed - indexed for MEDLINE]
17.

Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells.

Jang SY, Kim A, Kim JK, Kim C, Cho YH, Kim JH, Kim CH, Lee JY.

Anticancer Res. 2014 Aug;34(8):4127-34.

PMID:
25075039
[PubMed - indexed for MEDLINE]
18.

Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.

Wenhui Z, Shuo L, Dabei T, Ying P, Zhipeng W, Lei Z, Xiaohui H, Jingshu G, Hongtao S, Qingyuan Z.

Eur J Endocrinol. 2014 Oct;171(4):527-33. doi: 10.1530/EJE-14-0278. Epub 2014 Jul 28.

PMID:
25069458
[PubMed - indexed for MEDLINE]
19.

Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells.

Duan L, Danzer B, Levenson VV, Maki CG.

Cancer Lett. 2014 Oct 28;353(2):290-300. doi: 10.1016/j.canlet.2014.07.031. Epub 2014 Jul 25.

PMID:
25069039
[PubMed - indexed for MEDLINE]
20.

Interpreting the CYP2D6 results from the International Tamoxifen Pharmacogenetics Consortium.

Province MA, Altman RB, Klein TE.

Clin Pharmacol Ther. 2014 Aug;96(2):144-6. doi: 10.1038/clpt.2014.100. Review. No abstract available.

PMID:
25056393
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk